The efficacy of Papaverine Hydrochloride with Diclofenac Na in the treatment of acute renal colic

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138808251853N4

Enrollment

550

Registered

2009-11-16

Start date

2009-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic. Unspecified renal colic

Interventions

Intervention 1: Diclofenac Na, 100 mg, suppository plus papaverin 120 mg intravenous. Intervention 2: Diclofenac Na, 100 mg, suppository.

Treatment - Drugs

Diclofenac Na, 100 mg, suppository plus papaverin 120 mg intravenous

Diclofenac Na, 100 mg, suppository

Eligibility

Sex/Gender

All

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 15-55 years, symptoms of renal colic with any of the followings: hematuria detected by urine analysis, calculi detected by Genitourinary radiography or by sonography. Exclusion criteria: complete AV block, coronary artery disease, bronchial asthma, peptic ulcer disease, coagulopathy, anticougulat therapy, sensitivity to Dicolofenac or papaverin, renal or liver insufficiency, pregnancy, breast feeding, receiving any analgesics in the past 4 hours.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Renal colic pain. Timepoint: 10 month. Method of measurement: questionairre.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mani Mohiti Asl

Urology Research Center

urc@gums.ac.ir+98 13 1552 5259

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026